Glutamate transporter SLC1A6 promotes resistance to immunotherapy in cancer
SLC1A6 plays a critical role in resistance to immunotherapy in cancer. Targeting SLC1A6 may provide a promising therapeutic strategy for improving responses to neoadjuvant immunotherapy and advancing combination treatment approaches.
Authors
- Longhao Xu (ORCID: https://orcid.org/0000-0003-0040-7532)
- Hengda Zeng
- Haoran Zheng (ORCID: https://orcid.org/0000-0003-1885-8438)
- Chenchen Li
- Wenlong Zhong (ORCID: https://orcid.org/0000-0001-5343-4652)
- Daqin Wu (ORCID: https://orcid.org/0000-0002-6944-4158)
- Chunhui Wang (ORCID: https://orcid.org/0000-0003-0370-4989)
- Peicong Cai
- Yi Lin
- Shuai Liang (ORCID: https://orcid.org/0000-0001-8562-088X)
- Jianwen Lao
- Tianxin Lin
Institutions
- Sun Yat-sen University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-06-07
- DOI
- https://doi.org/10.1007/s00262-025-04074-4
- Primary Topic
- Amino Acid Enzymes and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangdong Province